373 related articles for article (PubMed ID: 9815929)
21. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Schwartz EL; Baptiste N; O'Connor CJ; Wadler S; Otter BA
Cancer Res; 1994 Mar; 54(6):1472-8. PubMed ID: 8137250
[TBL] [Abstract][Full Text] [Related]
22. Sequence and schedule-dependent synergy of trimetrexate in combination with 5-fluorouracil in vitro and in mice.
Elliott WL; Howard CT; Dykes DJ; Leopold WR
Cancer Res; 1989 Oct; 49(20):5586-90. PubMed ID: 2477146
[TBL] [Abstract][Full Text] [Related]
23. [Antiproliferative effect of interferon-alpha on human renal cell carcinoma in clonogenic assay--single and combination effect with cancer chemotherapeutic agent].
Ohmura K; Tsukamoto T
Hinyokika Kiyo; 1989 May; 35(5):737-47. PubMed ID: 2801371
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors.
Kogure T; Ueno Y; Iwasaki T; Shimosegawa T
Cancer Chemother Pharmacol; 2004 Apr; 53(4):296-304. PubMed ID: 14689231
[TBL] [Abstract][Full Text] [Related]
25. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
26. Regulation of thymidylate synthase in human colon cancer cells treated with 5-fluorouracil and interferon-gamma.
Chu E; Koeller DM; Johnston PG; Zinn S; Allegra CJ
Mol Pharmacol; 1993 Apr; 43(4):527-33. PubMed ID: 8474431
[TBL] [Abstract][Full Text] [Related]
27. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.
Tillman DM; Petak I; Houghton JA
Clin Cancer Res; 1999 Feb; 5(2):425-30. PubMed ID: 10037193
[TBL] [Abstract][Full Text] [Related]
28. Low folate conditions may enhance the interaction of trifluorothymidine with antifolates in colon cancer cells.
Temmink OH; Hoogeland MF; Fukushima M; Peters GJ
Cancer Chemother Pharmacol; 2006 Jan; 57(2):171-9. PubMed ID: 16010590
[TBL] [Abstract][Full Text] [Related]
29. Biochemical modulation of 5-fluorouracil with interferon alpha/beta and gamma on murine renal cell carcinoma.
Ishii T; Marumo K
Int J Urol; 2004 Nov; 11(11):993-1000. PubMed ID: 15509204
[TBL] [Abstract][Full Text] [Related]
30. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
Yeh KH; Yeh SH; Hsu CH; Wang TM; Ma IF; Cheng AL
Br J Cancer; 2000 Dec; 83(11):1510-5. PubMed ID: 11076661
[TBL] [Abstract][Full Text] [Related]
31. Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole.
Curtin NJ; Harris AL; Aherne GW
Cancer Res; 1991 May; 51(9):2346-52. PubMed ID: 2015598
[TBL] [Abstract][Full Text] [Related]
32. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
33. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 nonselected colon cancer cell lines.
van Triest B; Pinedo HM; van Hensbergen Y; Smid K; Telleman F; Schoenmakers PS; van der Wilt CL; van Laar JA; Noordhuis P; Jansen G; Peters GJ
Clin Cancer Res; 1999 Mar; 5(3):643-54. PubMed ID: 10100718
[TBL] [Abstract][Full Text] [Related]
34. Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid.
Moran RG; Scanlon KL
Cancer Res; 1991 Sep; 51(17):4618-23. PubMed ID: 1831402
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase II trial of 5-fluorouracil, with or without human interferon-beta, for advanced colorectal cancer.
Villar-Grimalt A; Candel MT; Massuti B; Lizón J; Sánchez B; Frau A; Gorostidi B; Goedkoop R
Br J Cancer; 1999 May; 80(5-6):786-91. PubMed ID: 10360656
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumour effect of raltitrexed and 5-fluorouracil plus folinic acid combination in human cancer cells.
Avallone A; Di Gennaro E; Bruzzese F; Laus G; Delrio P; Caraglia M; Pepe S; Comella P; Budillon A
Anticancer Drugs; 2007 Aug; 18(7):781-91. PubMed ID: 17581300
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.
van Laar JA; van der Wilt CL; Rustum YM; Noordhuis P; Smid K; Pinedo HM; Peters GJ
Clin Cancer Res; 1996 Aug; 2(8):1327-33. PubMed ID: 9816304
[TBL] [Abstract][Full Text] [Related]
38. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.
Schuetz JD; Wallace HJ; Diasio RB
Cancer Res; 1984 Apr; 44(4):1358-63. PubMed ID: 6704957
[TBL] [Abstract][Full Text] [Related]
39. Comparison of 5-fluorouracil metabolism in two human gastrointestinal tumor cell lines.
Washtien WL
Cancer Res; 1984 Mar; 44(3):909-14. PubMed ID: 6318987
[TBL] [Abstract][Full Text] [Related]
40. In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
Spears CP; Shahinian AH; Moran RG; Heidelberger C; Corbett TH
Cancer Res; 1982 Feb; 42(2):450-6. PubMed ID: 6173112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
